SCHEMBL337343

SCHEMBL337343

CCOC(=O)c1c(O)c2ncc(-c3ccccc3)nc2n(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.51
ALDH1A1 P00352 8/20 0.51
TSHR P16473 2/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 2/20 0.46
RECQL P46063 1/20 0.46
GAA P10253 4/20 0.44
LMNA P02545 4/20 0.44
MAPT P10636 4/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CCR6 P51684 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337011 0.80 EGLN1 (0.56)
SCHEMBL337676 0.77 ALDH1A1 (0.58) KDM4EALDH1A1TSHRNPC1RAB9A
SCHEMBL12291956 0.72 ALDH1A1 (0.56) KDM4EALDH1A1TSHRNPC1SMN1; SMN2
SCHEMBL11160274 0.72 RECQL (0.61) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL8137427 0.71 ALDH1A1 (0.65) KDM4EALDH1A1NPC1SMN1; SMN2RECQL
SCHEMBL8141322 0.71 ALDH1A1 (0.61) KDM4EALDH1A1TSHRNPC1RAB9A
SCHEMBL2578402 0.71 KDM4E (0.52) KDM4EALDH1A1TSHRNPC1RAB9A
SCHEMBL8137044 0.71 ALDH1A1 (0.57) KDM4EALDH1A1TSHRNPC1RAB9A
SCHEMBL7965215 0.70 NPC1 (0.58) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL11157510 0.70 KDM4E (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 US disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN KDM4E 248/4885ALDH1A1 108/4885TSHR 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.